Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
ABSTRACT: to compare the
immunoexpression of BRAF V600E among stage of colorectal cancer. Methods: this was
a cross sectional, and retrospective study involving Dukes’ stage A, B, and C
colorectal carcinoma, each with 15 cases. Immunohistochemistry was performed in
paraffn-embedded specimens of tumor mass for the assessment of BRAF V600E. The
proportion differences of immunoexpression of BRAF V600E among Dukes’stage A,
B, and C were tested using Chi-Square test. Results: the result of positive
BRAF V600E immunoexpression (moderately to strongly positive) in Dukes’stage A,
B, and C were found in 1 of 15 cases, 4 of 15 cases and 13 of 15 cases
respectively. BRAF V600E immunoexpression was statistically signifcant more
frequent in Dukes’stage C (p<0,001, Chi-Square test). Conclusion: positive
BRAF V600E immunoexpression could be used as a marker of aggresive colorectal
carcinoma.
Author: Bethy S. Hernowo,
Fenny Ariyanni, Sri Suryanti, Abdul H. Hassan
Journal Code: jpkedokterangg140275